Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
$24.80
-2.2%
$22.58
$16.50
$26.55
$2.16BN/A59,833 shs5,409 shs
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$3.39
-1.6%
$3.27
$2.71
$4.73
$650.23M1.5991,422 shs91,397 shs
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$13.78
-0.6%
$14.10
$11.51
$21.50
$2.40B0.55100,430 shs30,373 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$14.74
-1.0%
$15.06
$12.72
$34.47
$2.50B0.751.54 million shs242,117 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
+3.77%-0.82%+4.75%+33.21%+2,534,999,900.00%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
+0.88%+6.83%+0.88%-0.29%+2.38%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
+4.76%+4.45%-8.58%-15.80%-25.72%
Immunovant, Inc. stock logo
IMVT
Immunovant
+5.60%+2.27%-2.17%-27.72%-49.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/AN/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
2.3128 of 5 stars
3.50.00.00.03.82.50.6
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.0112 of 5 stars
3.02.00.00.02.20.01.9
Immunovant, Inc. stock logo
IMVT
Immunovant
2.2696 of 5 stars
4.50.00.00.02.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
3.00
BuyN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5063.45% Upside
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
2.00
Hold$19.0036.90% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33163.59% Upside

Current Analyst Ratings Breakdown

Latest ABUS, IMVT, HCM, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
4/22/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00
3/28/2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/27/2025
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/20/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/20/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
3/19/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$51.00 ➝ $51.00
3/10/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/4/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/3/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$20.00
3/2/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMixed ➝ Mixed
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
$980.65M2.20N/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$6.40M100.65N/AN/A$0.63 per share5.34
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$630.20M3.84$0.57 per share24.51$4.27 per share3.25
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$2.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/A0.00N/AN/AN/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
$100.78MN/A0.009.51N/AN/AN/AN/A6/18/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)

Latest ABUS, IMVT, HCM, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/AN/A
5/14/2025Q1 2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
3/27/2025Q4 2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/A
7.02
7.02
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
0.07
2.81
2.68
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
6.04
6.04

Institutional Ownership

CompanyInstitutional Ownership
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
43.79%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
8.82%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%

Insider Ownership

CompanyInsider Ownership
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
N/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
20.30%
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
3.60%
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International stock logo
AAPG
Ascentage Pharma Group International
60087.07 millionN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
90191.53 million181.91 millionOptionable
HUTCHMED (China) Limited stock logo
HCM
HUTCHMED
1,760174.32 million168.04 millionNot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120169.86 million159.84 millionOptionable

Recent News About These Companies

Immunovant, Inc. stock logo
Immunovant (NASDAQ:IMVT) Shares Gap Up on Earnings Beat
Immunovant, Inc. stock logo
Immunovant (IMVT) to Release Earnings on Wednesday
Immunovant (IMVT) Expected to Announce Earnings on Wednesday
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $38.33

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$24.80 -0.55 (-2.17%)
As of 11:16 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.38 -0.06 (-1.60%)
As of 11:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$13.78 -0.09 (-0.61%)
As of 11:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$14.74 -0.15 (-1.01%)
As of 11:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.